Business Context and Reporting Period
Company: Verastem, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2011
Business Overview: Verastem is a clinical-stage biopharmaceutical company focused on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) in breast and other cancers, alongside companion diagnostics. The company utilizes proprietary technology based on the epithelial-to-mesenchymal transition (EMT) to create stable populations of CSCs for high-throughput screening. As of the reporting date, the company had no commercial products and had not generated any revenue.
Key Financial Metrics
| Metric | Year Ended Dec 31, 2011 | Period from Inception (Aug 4, 2010) to Dec 31, 2010 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(13.7) million | $(0.8) million |
| Accumulated Deficit | $(14.5) million | $(0.8) million |
| Research & Development Expenses | $9.9 million | $0.4 million |
| General & Administrative Expenses | $3.8 million | $0.4 million |
| Cash, Cash Equivalents & Investments | $56.8 million | $3.6 million |
| Working Capital | $44.8 million | $3.2 million |
| Debt | None reported | None reported |
Note: All financial figures are in millions unless otherwise noted. The company is classified as a development-stage entity.
Material Changes vs. Prior Period
- Significant Increase in Operating Expenses: Total operating expenses surged from $0.8 million in the partial 2010 period to $13.7 million in 2011. This increase was driven by expanded research and development activities, including hiring, external contract research organization (CRO) fees, and license fees.
- Capital Raising: The company raised substantial capital through private placements of Series A, B, and C preferred stock in 2011, resulting in net proceeds of approximately $64.2 million for the year. This significantly improved liquidity compared to the $3.6 million in cash held at the end of 2010.
- Investment Portfolio: The company began investing excess cash in short-term and long-term investments (government securities and commercial paper) in 2011, holding $35.9 million in investments by year-end, compared to none in 2010.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Clinical Trials: Management expects to initiate clinical trials with lead product candidates VS-507 and one of either VS-4718 or VS-5095 within 12 to 15 months of the filing date (early 2013).
- Capital Runway: Following an Initial Public Offering (IPO) completed in February 2012 (raising $56.7 million in net proceeds), management expects to fund operations and capital expenditures into 2016.
- Profitability: The company expects to incur significant losses for the foreseeable future and may never achieve profitability.
Key Risks and Contingencies:
- Need for Additional Capital: The company has no revenue and relies on equity financing. Failure to raise additional capital could force delays or termination of development programs.
- Preclinical Stage: All product candidates are in preclinical development. There is no guarantee that preclinical results will translate to human efficacy or safety.
- Intellectual Property: The company relies on licenses from the Whitehead Institute, Broad Institute, and Poniard Pharmaceuticals. Failure to comply with license terms could result in termination of rights.
- Regulatory Approval: The company has no experience in obtaining FDA approval for drugs or companion diagnostics, which are subject to rigorous and uncertain regulatory processes.
Investor Verification Checklist
- Cash Burn Rate: Verify the monthly burn rate based on the $13.7 million annual loss to assess the sustainability of the projected 2016 runway.
- License Obligations: Review the specific milestone payment triggers and royalty rates in the agreements with the Whitehead Institute and Poniard Pharmaceuticals to understand future cash outflows.
- Product Pipeline Progress: Monitor the status of IND-enabling toxicology studies for VS-507, VS-4718, and VS-5095 to confirm the timeline for clinical trial initiation.
- Related Party Transactions: Review the significant ownership stakes held by directors and executive officers (approx. 56% combined) and their participation in the IPO and preferred stock financings.
- Stock-Based Compensation: Assess the impact of future equity grants on dilution, given the company's reliance on stock options to attract talent.